Chronic Granulomatous Disease (CGD)
7
3
3
1
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 7 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (7)
Evaluation of Patients With Immune Function Abnormalities
Part B- G1X-CGD (Lentiviral Vector Transduced CD34+ Cells) in Patients With X-Linked Chronic Granulomatous Disease
Base Editing for Mutation Repair in Hematopoietic Stem & Progenitor Cells for X-Linked Chronic Granulomatous Disease
Prevalence of Antibodies and Cytokines in Participants With Chronic Granulomatous Disease
Sequential Cadaveric Lung and Bone Marrow Transplant for Immune Deficiency Diseases
Skin Immunity Sample Collection Involving Blisters and Biopsies
Non-Invasive Assessment of Atherosclerosis in Patients With CGD and Other Disorders of the Immune System